Login to Your Account

Adventrx Moves Into Phase III With CoFactor, Pulls Offering

By Jennifer Boggs

Tuesday, May 23, 2006
Adventrx Pharmaceuticals Inc. and the FDA have agreed on a special protocol assessment for a Phase III trial of its chemotherapy enhancing drug, CoFactor, expected to start this quarter. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription